期刊文献+

2015年江西抚州市第一人民医院临床分离菌耐药性分析 被引量:3

Antimicrobial resistance profile of the clinical isolates in Fuzhou First People's Hospital,Jiangxi during 2015
下载PDF
导出
摘要 目的了解江西省抚州市第一人民医院2015年临床分离菌分布及耐药状况。方法采用ATB Reader半自动仪器比色法进行菌种鉴定,纸片扩散法进行药敏试验,参照CLSI 2015年版标准判读结果,WHONET5.5软件进行数据分析。结果该院2015年共收集非重复临床分离菌1 215株,其中革兰阴性菌858株,占70.6%,革兰阳性菌357株,占29.4%。耐甲氧西林金黄色葡萄球菌(金葡菌,MRSA)和耐甲氧西林凝固酶阴性葡萄球菌(MRCNS)分别占金葡菌和凝固酶阴性葡萄球菌的50.0%和84.1%;MRSA对红霉素高度耐药、对四环素和诺氟沙星耐药率均为80.3%,未见耐万古霉素和替考拉宁葡萄球菌。大肠埃希菌和肺炎克雷伯菌中产ESBL株分别占52.5%和34.7%;检出碳青霉烯类耐药肠杆菌科细菌10株。铜绿假单胞菌对阿米卡星、头孢哌酮-舒巴坦、美罗培南和妥布霉素的耐药率均低于10%。鲍曼不动杆菌对黏菌素和头孢哌酮-舒巴坦的耐药率分别为2.4%和51.8%,对其他常用抗菌药物的耐药率均在75%以上。结论该院临床分离菌以革兰阴性杆菌为主,细菌耐药性仍是临床重要问题,应引起临床高度重视。 Objective To investigate the antimicrobial resistance profile of clinical isolates in Fuzhou First People's Hospital during 2015. Methods The bacterial isolates were identified using ATB Reader semi-automatic equipment via colorimetric method. The antimicrobial susceptibility was tested by disk diffusion method. The results were interpreted according to the CLSI breakpoints issued in 2015. All data were analyzed by WHONET 5.5 software. Results A total of 1 215 non-duplicate clinical isolates were collected during 2015, including gram negative bacteria (70.6 %) and gram positive bacteria (29.4 %). The prevalence of MRSA was 50.0 % in S. aureus and the prevalence of MRCNS was 84.1% in coagulase-negative Staphylococcus. Most MRSA strains (80.3 %) were resistant to erythromycin, tetracycline and norfloxacin. No staphylococcal isolate was found resistant to vancomycin or teicoplanin. The prevalence of ESBLs was 52.5 % in E. coli and 34.7 % in K. pneumoniae. Ten strains of Enterobacteriaceae were resistant to carbapenems. Less than 10 % of the P aeruginosa isolates were resistant to amikacin, cefoperazone-sulbactam, meropenem and tobramycin. About 2.4 % and 51.8 % of the Acinetobacter isolates were resistant to polymyxin E and cefoperazone-sulbactam, respectively, while more than 75 % of these strains were resistant to other commonly used antimicrobial agents. Conclusions Most of the clinical isolates are gram-negative bacilli in our hospital during 2015. Antimicrobial resistance remains an important clinical concern, which should be addressed seriously.
出处 《中国感染与化疗杂志》 CAS CSCD 北大核心 2017年第2期171-176,共6页 Chinese Journal of Infection and Chemotherapy
基金 江西省卫生计生委科技计划项目(20164071)
关键词 抗菌药物 药敏试验 耐药性分析 antimicrobial agent antimicrobial susceptibility testing antimicrobial resistance profile
  • 相关文献

参考文献6

二级参考文献59

  • 1骆俊,朱德妹,徐晓刚,吴卫红,王明贵,张婴元,汪复.泛耐药弗劳地柠檬酸杆菌产β内酰胺酶及同源性[J].中华传染病杂志,2006,24(5):291-295. 被引量:20
  • 2Rahal JJ. The role of carbapenems in initial therapy for serious Gram-negative infections[J]. Crit Care, 2008,12 ($4) : 5.
  • 3Yigit H, Queenan AM, Anderson GJ, et al. Novel earbapen- em-hydrolyzing beta-laetamase, KPC-1, from a earbapenem-re- sistant strain of Klebsiella pneumoniae [J]. Antimierob Agents Chemother,2001,45(4) : 1151-1161.
  • 4Vatopoulos A. High rates of metallo-beta-lactamase-producing Klebsiella pneumoniae in Greece-a review of the current evi- dence[J]. Euro Surveill, 2008,13 (4), pii : 8023.
  • 5Oteo J, Delgado-Iribarren A, Vega D, et al. Emergence of imipen- em resistance in clinical Escherichia coli during therapy[J], lnt J Antimicrob Agents, 2008,32 (6) : 534-537.
  • 6Kaczmarek FM, Dib-Hajj F, Shang W, et al. High-level carbapen- em resistance in a Klebsiella pneumoniae clinical isolate is due to the combination of bla (ACT-1) beta-lactamase production ,porin OmpK35/36 insertional inactivation, and down-regulation of the phosphate transport porin phoe [J]. Antimicrob Agents Chemoth- er, 2006,50 (10) : 3396-3406.
  • 7Queenan AM, Bush K. Carbapenemases: the versatile beta-lacta- mases[J]. Clin Mierobiol Rev, 2007,20 (3) : 440-458.
  • 8Yigit H, Anderson G J, Biddle JW, et al. Carbapenem resistance in a clinical isolate of Enterobacter aerogenes is associated with de- creased expression of OmpF and OmpC porin analogs[J]. Antimi- crob Agents Chemother, 2002,46 ( 12 ) : 3817-3822.
  • 9Villar HE, Danel F, Livermore DM. Permeability to carbapenems of Proteus mirabilis mutants selected for resistance to imipenem or other beta-lactams[J]. J Antimicrob Chemother, 1997,40 (3) : 365-370.
  • 10Castanheira M, Mendes RE, Woosley LN, et al. Trends in car- bapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas : report from the SENTRYantimicrobial surveillance programme (2007-09)[J]. J Antimicrob Chemother, 2011,66(6) : 1409-1411.

共引文献1129

同被引文献25

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部